ClinicalTrials.gg
RecruitingNCT07808619Updated Sep 9, 2026

Longevity Metrics AI/ML Development Study

An observational study in Aging, Mortality and Cardiovascular Disease Prevention, sponsored by Longevity Metrics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Longevity Metrics, Inc. · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000,000
Ages
18 Years and older
Sex
All
01

Study summary

This study builds AI models that score diagnostic screening tests, and that predict screening results, clinical judgment, and life expectancy. Longevity Metrics collects a battery of clinical tests on each participant, in whole or in part, and follows every participant for life.

The sit-to-rise test and the timed walk are scored by hand today, from a person's count. A model scores the same test from video instead. It also measures what no one can count by eye - speed, asymmetry, steadiness - so one capture yields both the original score and additional measurements, intended to enrich the model and strengthen what it predicts.

Every test in a participant's record measures the same body, so the tests are correlated: a test that was performed carries information about one that was not. A model trained across the library learns those relationships and estimates a missing result from the results that are present. Each estimate is checked against records where that part was actually measured, and over decades against death and disease through linkage to the 100-Year Human Aging Study (NCT07563777).

The hypothesis is that the full battery can eventually be predicted across modalities with high accuracy using a few short video clips, replacing most in-person screening. That would let preventive screening reach people and places a physical laboratory cannot. How far the input can be reduced is the question this study exists to answer.

Every model is a physician-reviewed clinical decision aid until it is cleared by the FDA.

Read the detailed description

The models serve three aims. First, they automatically score simple physical and cognitive tests that already predict function and in some cases mortality, such as the sit-to-rise test and the timed walk. A model reads richer detail from the same recording than a human scorer can, so it improves on the human score rather than only reproducing it.

Second, they predict the parts of a screening a participant did not obtain from the parts that were performed, and increasingly from inexpensive standardized inputs such as a short video. Within a single record, every test is correlated with the others, so each test can both predict the ones that were not performed and serve as the truth against which those predictions are checked. A missing-data engine fills any missing part of a record by leave-one-out across the library.

Third, they predict the physician's clinical judgment where no determining measurement exists.

Models are developed by milestone freezing with forward validation. No model is validated on records it was trained on. Each model is validated in two stages. It is first validated against a human scorer for measurement accuracy, which gates its use as a clinical decision aid. It is then validated over decades for what it predicts about death and disease.

The platform's distinguishing asset is mortality. Every participant is followed for life, so a small library with verified death outcomes answers questions a much larger library without them cannot. The library is the durable asset, studied across geography and time by increasingly capable models.

This study is one of four that compound into one system. The 100-Year Human Aging Study (NCT07563777) supplies the clinical data and validates what it means for health, disease, disability, and death. The Human Observatory Study (NCT07646782) does the same with sociodemographic and environmental data, and receives each model's geographic residuals. The Health Ahead Comparative Effectiveness Study (NCT07669168) moves the screening toward increasing automation and mobility while maintaining quality. This study builds the models that make automation, prediction, and broad utilization possible.

A physician or licensed provider reviews and signs every result a participant receives.

02

Conditions studied

  • Aging
  • Mortality
  • Cardiovascular Disease Prevention
  • Metabolic Syndrome
  • Cognitive Dysfunction
  • Frailty
  • Musculoskeletal Diseases
  • Activities of Daily Living
  • Physical Disability
  • Preventive Health Services
  • Health Services Accessibility
  • Diagnostic Techniques and Procedures

Keywords

  • Longevity
  • Preventive Health
  • Health Screening
  • Biological Age
  • Artificial Intelligence
  • Machine Learning
  • Computer Vision
  • Sit to Rise
  • Gait Speed
  • Pose Estimation
  • All-Cause Mortality
  • Life Expectancy Prediction
  • Healthspan
  • Preventive Medicine
  • Functional Decline
  • Human Performance
03

In context

Metabolic Syndrome

2,116 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.

This study's planned enrollment of 1,000,000 is above the median of 197 across 496 observational studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Longevity Metrics, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants enrolled in the 100-Year Human Aging Study (NCT07563777) through the unified consent, receiving any Longevity Metrics health screening service at any fixed, mobile, or remote (online) site, current and future. Participants are self-selected community members of all health statuses; no exclusions based on health status, diagnosis, or population group. This study adds no separate enrollment: all records analyzed and all prospective measurements collected under this protocol arise from participants consented under the associated protocols. Participants are followed for life, with mortality, incident disease, and functional-status outcomes ascertained through linkage to the 100-Year Human Aging Study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18
  • willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testAIML scored health screening battery

    Video and audio-captured physical, cognitive, and observational screening tests scored by frozen, versioned AI models; models automatically score standard tests (sit-to-rise, timed walk, chair stand), predict non-performed results from performed ones, and predict clinical judgment; all outputs are physician-reviewed clinical decision aids, and no model output reaches a participant report without provider confirmation.

06

What researchers measure

Primary outcomes

  1. Measurement Accuracy, Non-Inferiority to Human Scoring.

    Agreement between the model's value and the reference standard, established as non-inferiority to a qualified human scorer where a human reference exists. Gates deployment as a clinical decision aid.

    Time frame: At each model freeze, through study completion, up to 100 years.

  2. Cross-Prediction of Non-Performed Results and Derived Scores

    Accuracy of predicting, from video or from the performed part of a record, both the screening results the participant did not obtain, against the measured value; and the derived scores computed from a complete record, including the Longevity Score, biological age, and estimated age at death, against the value the scoring engine produces from the full measured record.

    Time frame: At each model freeze, through study completion, up to 100 years.

  3. Prediction of Remaining Life Expectancy

    Accuracy of predicting remaining life expectancy from video and library data, against observed mortality through linkage to the 100-Year Human Aging Study.

    Time frame: Through study completion, up to 100 years

  4. Prediction of Physician Clinical Judgment

    Accuracy of predicting the physician's clinical judgment where no determining measurement exists, against the sealed record. Applies to models that predict a clinical determination rather than a measured value. Where a determining test exists but was not performed, the outcome falls under Primary Outcome 2.

    Time frame: At each model freeze, through study completion, up to 100 years

  5. Screening-Related Injuries and Adverse Events

    Participant injuries or adverse events attributed to measurements added under this study, such as the sit-to-rise test. Ascertained from two independent sources so that an event missed by one is still captured: the tester logs any fall or injury at the time of screening, and the participant reports separately on the post-screening form.

    Time frame: Continuously from first screening through study completion, up to 100 years

Secondary outcomes

  1. Measurement Accuracy, Superiority to Human Scoring

    Conditional on non-inferiority, whether the model scores more reliably or precisely than a qualified human scorer.

    Time frame: At each model freeze, through study completion, up to 100 years

  2. Uncertainty Calibration

    Agreement between the model's stated confidence and its observed accuracy.

    Time frame: At each model freeze, through study completion, up to 100 years

  3. Within-Session Repeatability

    Where a test is captured twice back to back, the stability of the model's output across the two captures. Not applicable where repeat capture is impractical, or where a second effort measures fatigue because the test is performed to failure.

    Time frame: At each model freeze, through study completion, up to 100 years.

  4. Missing-Data and Completeness Robustness

    Model performance on partial or incomplete input relative to complete input.

    Time frame: At each model freeze, through study completion, up to 100 years

  5. Physician Assessment of Model Output

    Three physician-recorded fields per result, identical to the structured judgment recorded under the Health Ahead Comparative Effectiveness Study, so that one instrument governs physician review of model output across the platform. Agreement with the model read, 1 to 10, 1 strongly disagree to 10 strongly agree. Safety, the potential for patient harm had the read been acted upon as written, 1 to 10, 1 high potential for serious harm to 10 no potential for patient harm. Override, binary, recording whether the released interpretation differs in any substantive respect from the read. The two rating scales ascend toward the better state. Agreement records what the physician thought of a read; override records what the physician did with it, and the two diverge routinely.

    Time frame: Continuously from first model read through study completion, up to 100 years

  6. Model Enrichment

    Whether added parameters improve prediction of 100-Year outcomes over the base measure. Reported once Primary Outcome 3 is estimable.

    Time frame: Through study completion, up to 100 years.

  7. Improvement Over Standard Screening

    Incremental value of video-derived information over standard screening for remaining life expectancy, through the 100-Year linkage. Reported once Primary Outcome 3 is estimable.

    Time frame: Through study completion, up to 100 years

  8. Incident Chronic Disease Prediction

    Accuracy of predicting new chronic disease onset, through the 100-Year linkage. Reported by predictor set, model and physician, so the prognostic comparison is made on a common outcome.

    Time frame: Through study completion, up to 100 years

  9. Cause-of-Death Prediction

    Concordance between predicted and actual cause of death, through the 100-Year linkage.

    Time frame: Through study completion, up to 100 years

  10. Time to Functional Disability

    Accuracy of predicting the timing of functional disability onset, through the 100-Year linkage.

    Time frame: Through study completion, up to 100 years

  11. Geographic Predictive Transportability

    Change in predictive performance with environmental distance from the validated envelope. Residuals are returned to the Human Observatory Study.

    Time frame: At each model freeze, through study completion, up to 100 years

  12. Temporal Stability and Drift

    Stability of performance across calendar time and across a participant's repeat screenings.

    Time frame: Continuously from first model freeze through study completion, up to 100 years

  13. Rate of Change

    Accuracy of predicting the change in a measure between visits, and of predicting outcomes from that change. Applies to every model with repeat captures. The within-participant change and its pace are tested against death, disease, and functional decline alongside the cross-sectional value.

    Time frame: Through study completion, up to 100 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not shared. The complete participant record includes facial and voice recordings, genomic data, and neighborhood-resolution geography, and cannot be de-identified; it is never released. Identifiable data are accessed only by approved researchers working within Longevity Metrics secure facilities under data use agreements, with no data removed. Specific derived, aggregate, and statistical outputs are de-identified to HIPAA Safe Harbor standards and may be published, shared with collaborators, or contributed to open-access research databases. Models, risk estimates, and analytic findings derived from the research data may be provided to external organizations or used commercially; no participant record and no dataset containing participant data is transferred.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07808619
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Aug 8, 2026
Primary completion
Dec 31, 2099 (estimated)
Completion
Dec 31, 2099 (estimated)
Last update
Sep 9, 2026

Study contacts

William E Brandenburg, MD
Contact
info@longevitymetrics.org
3035010016
William E Brandenburg, MD
principal investigator · Longevity Metrics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion